Welcome
Support Centre
25 July 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Evaluation of H. pylori infection in aspirin users - pilot study
ISRCTN ISRCTN10740230
ClinicalTrials.gov identifier
Public title Evaluation of H. pylori infection in aspirin users - pilot study
Scientific title Helicobacter pylori Eradication vs Aspirin Toxicity pilot study
Acronym HEAT
Serial number at source G0700648
Study hypothesis Eradication of H. pylori in patients taking aspirin regularly will reduce the risk of ulcer bleeds.
Ethics approval Nottingham 2 Research Ethics Committee, approved on 21 September 2007.
Study design Part 1: Interventional, non-randomised controlled study. Part 2: Observational database study.
Countries of recruitment United Kingdom
Disease/condition/study domain Ulcer bleeding
Participants - inclusion criteria 1. Male and female patients aged 45 years of age or older
2. Patients who have given written informed consent
3. Patients taking aspirin (less than or equal to 300 mg daily)
NB: Patients who have previously been tested for H. pylori and/or had previous eradication therapy will not be excluded.
Participants - exclusion criteria 1. Patients currently taking anti-ulcer therapy (H2-receptor antagonists i.e. cimetidine, famotidine, nizatidine or ranitidine and Proton Pump Inhibitors [PPIs] i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole sodium)
2. Patients currently taking non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (aceclofenac, acemetacin, azapropazone, dexibuprofen, dexketoprofen, diclofenac sodium, diflunisal, fenbufen, fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen, mefenamic acid, meloxicam, nabumetone, naproxen, piroxicam, sulindac, tenoxicam, or tiaprofenic acid)
3. Patients who are terminally ill
4. Patients who are allergic to any of the eradication treatment drugs
5. Patients who are currently being treated with an antibacterial or have had antibacterial treatment within the last 4 weeks
6. Patients who have had treatment with a PPI (listed above) within the last 2 weeks.
7. Women who are pregnant or breast feeding
Anticipated start date 01/02/2008
Anticipated end date 31/07/2008
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 905
Interventions This trial has two parts:

Part 1: Interventional study. This study will establish the H. pylori infection rates and success of eradication therapy.

GPs will screen their patient records for potential participants (Aged >45 and on <300 mg aspirin/day, excluding ulcer healing drugs and NSAIDs) and write to them to invite them to take part in the study. All participants will have a 13C Urea breath test (to establish their H. pylori status) and a blood sample taken (for future H. pylori serology testing). For participants who test negative for H. pylori, this will be the end of their involvement in the study. All patients who test positive for H. pylori (there will be no randomisation) will be given eradication therapy (Clarithromycin 500 mg twice a day [bd], omeprazole 20 mg bd and metronidazole 400 mg bd. Eradication treatment will last 7 days), and retested 6-8 weeks later to test eradication success.

Part 2: Observational study. This is a database study to assess aspirin use in the target population and rates of ulcer bleeds.
Primary outcome measure(s) 1. Rate of aspirin use (results of Part 2 Observational study)
2. Rate of ulcer bleeding in patients using aspirin (results of Part 2 Observational study)
3. Level of H. pylori infection and subsequent eradication rates in aspirin patients at 6-8 weeks after the eradication therapy
4. Level of interest from GPs and patients for a randomised study and their preferred enrolment site
Secondary outcome measure(s) No secondary outcome measures
Sources of funding Medical Research Council (UK)
Trial website
Publications
Contact name Prof  Chris  Hawkey
  Address Wolfson Digestive Diseases Centre
University Hospital
  City/town Nottingham
  Zip/Postcode NG7 2UH
  Country United Kingdom
  Tel +44 (0)115 8231033
  Email cj.hawkey@nottingham.ac.uk
Sponsor University of Nottingham (UK)
  Address Research Innovation Services
King's Meadow Campus
Lenton Lane
  City/town Nottingham
  Zip/Postcode NG7 2NR
  Country United Kingdom
  Tel +44 (0)115 9515679
  Email paul.cartledge@nottingham.ac.uk
Date applied 07/01/2008
Last edited 28/04/2008
Date ISRCTN assigned 27/03/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central